Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

Group sales In the first nine months of 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 45.9 billion due to strong demand for our pharmaceutical and diagnostic products.

On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients ...

Endometrial cancer treatment and body image challenges often go hand in hand. Here’s how to cope and rebuild confidence after treatment.

India's path towards strong crypto compliance is strategic and symbolic. It signals the country's determination to be a ...